Vindesine Sulfate en es it fr

Vindesine Sulfate Brand names, Vindesine Sulfate Analogs

Vindesine Sulfate Brand Names Mixture

  • No information avaliable

Vindesine Sulfate Chemical_Formula


Vindesine Sulfate RX_link

Vindesine Sulfate fda sheet

Vindesine Sulfate msds (material safety sheet)

Vindesine Sulfate Synthesis Reference

G. J. Cullinan, K. Gerzon, Ger. pat. 2,415,980 (1974 to Lilly)

Vindesine Sulfate Molecular Weight

753.926 g/mol

Vindesine Sulfate Melting Point

230-232 oC

Vindesine Sulfate H2O Solubility

No information avaliable

Vindesine Sulfate State


Vindesine Sulfate LogP


Vindesine Sulfate Dosage Forms

IM solution; Powder for solution

Vindesine Sulfate Indication

For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis

Vindesine Sulfate Pharmacology

Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.

Vindesine Sulfate Absorption

No information avaliable

Vindesine Sulfate side effects and Toxicity

No information avaliable

Vindesine Sulfate Patient Information

Patient Information:

The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause
loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black
stool, bruising or bleeding.

Patients should be informed that the major acute toxicities of Vindesine are related to bone
marrow toxicity, specifically granulocytopenia with increased susceptibility to infection.
They should be advised to report fever or chills immediately. Women of childbearing potential
should be advised to avoid becoming pregnant during treatment. Patients should be advised to
contact their physician if they experience increased shortness of breath, cough, or other new
pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.

Vindesine Sulfate Organisms Affected

Humans and other mammals